Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Guselkumab
- drug: Placebo for guselkumab
- drug: Etanercept
Eligibility
Inclusion Criteria:
- Have a diagnosis of chronic plaque-type psoriasis for at least 6 months (with or
without psoriatic arthritis [PsA]), prior to first administration of study
intervention, defined as having at screening and baseline, Investigator Global
Assessment (IGA) greater than or equal to (>=) 3, Psoriasis Area and Severity Index
(PASI) >=12, >=10% body surface area (BSA) involvement and at least one of the
following: very thick lesions, clinically relevant facial, genital, or hand/ foot
involvement, PASI>=20, >20% BSA involvement, or IGA=4
- Be a candidate for phototherapy or systemic treatment of plaque psoriasis (either
naive or history of previous treatment)
- Have plaque psoriasis considered by the investigator as inadequately controlled with
phototherapy and/or topical therapy after an adequate dose and duration of therapy
- Be considered, in the opinion of the investigator, a suitable candidate for etanercept
therapy, according to their country's approved Enbrel product labeling
- Be otherwise healthy on the basis of physical examination, medical history, and vital
signs performed at screening. Any abnormalities, must be consistent with the
underlying illness in the study population and this determination must be recorded in
the participant's source documents and initialed by the investigator
- Must have acceptable evidence of immunity to varicella and measles, mumps, and rubella
(MMR), which includes any one of the following: documentation of age-appropriate
vaccination that includes both doses of each vaccine (unless local guidelines specify
otherwise) or documentation of past infection by a healthcare provider or in the
absence of previous 2 criteria, participants must have positive protective antibody
titers to these infection prior to the first administration of study intervention. For
participants who have not completed the recommended vaccination schedule for varicella
and MMR, and the subsequent vaccination falls within the next 4 years, an accelerated
vaccination schedule must be completed prior to study enrollment if available and
required or strongly recommended for the location. If varicella or MMR vaccines are
utilized, it is necessary for 2 weeks to elapse between the vaccination and receipt of
study intervention
Exclusion Criteria:
- Currently has nonplaque forms of psoriasis (example, erythrodermic, guttate, or
pustular)
- Has current drug-induced psoriasis (example, a new onset of psoriasis or an
exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Has previously received guselkumab or etanercept
- Has a history of chronic or recurrent infectious disease, including but not limited to
chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent
urinary tract infection (recurrent pyelonephritis or chronic non-remitting cystitis),
fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin
wounds or ulcers
- Has a known history of lymphoproliferative disease, including lymphoma; a history of
monoclonal gammopathy of undetermined significance (MGUS); or signs and symptoms
suggestive of possible lymphoproliferative disease, such as lymphadenopathy or
splenomegaly
Ages Eligible for Study
6 Years - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pediatric Dermatology
650-723-0636
I'm interested
Psoriasis Clinical Trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Guselkumab
- drug: Placebo for guselkumab
- drug: Etanercept
Eligibility
Inclusion Criteria:
- Have a diagnosis of chronic plaque-type psoriasis for at least 6 months (with or
without psoriatic arthritis [PsA]), prior to first administration of study
intervention, defined as having at screening and baseline, Investigator Global
Assessment (IGA) greater than or equal to (>=) 3, Psoriasis Area and Severity Index
(PASI) >=12, >=10% body surface area (BSA) involvement and at least one of the
following: very thick lesions, clinically relevant facial, genital, or hand/ foot
involvement, PASI>=20, >20% BSA involvement, or IGA=4
- Be a candidate for phototherapy or systemic treatment of plaque psoriasis (either
naive or history of previous treatment)
- Have plaque psoriasis considered by the investigator as inadequately controlled with
phototherapy and/or topical therapy after an adequate dose and duration of therapy
- Be considered, in the opinion of the investigator, a suitable candidate for etanercept
therapy, according to their country's approved Enbrel product labeling
- Be otherwise healthy on the basis of physical examination, medical history, and vital
signs performed at screening. Any abnormalities, must be consistent with the
underlying illness in the study population and this determination must be recorded in
the participant's source documents and initialed by the investigator
- Must have acceptable evidence of immunity to varicella and measles, mumps, and rubella
(MMR), which includes any one of the following: documentation of age-appropriate
vaccination that includes both doses of each vaccine (unless local guidelines specify
otherwise) or documentation of past infection by a healthcare provider or in the
absence of previous 2 criteria, participants must have positive protective antibody
titers to these infection prior to the first administration of study intervention. For
participants who have not completed the recommended vaccination schedule for varicella
and MMR, and the subsequent vaccination falls within the next 4 years, an accelerated
vaccination schedule must be completed prior to study enrollment if available and
required or strongly recommended for the location. If varicella or MMR vaccines are
utilized, it is necessary for 2 weeks to elapse between the vaccination and receipt of
study intervention
Exclusion Criteria:
- Currently has nonplaque forms of psoriasis (example, erythrodermic, guttate, or
pustular)
- Has current drug-induced psoriasis (example, a new onset of psoriasis or an
exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Has previously received guselkumab or etanercept
- Has a history of chronic or recurrent infectious disease, including but not limited to
chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent
urinary tract infection (recurrent pyelonephritis or chronic non-remitting cystitis),
fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin
wounds or ulcers
- Has a known history of lymphoproliferative disease, including lymphoma; a history of
monoclonal gammopathy of undetermined significance (MGUS); or signs and symptoms
suggestive of possible lymphoproliferative disease, such as lymphadenopathy or
splenomegaly
Ages Eligible for Study
6 Years - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pediatric Dermatology
650-723-0636
I'm interested
Dermatology Clinical Trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Guselkumab
- drug: Placebo for guselkumab
- drug: Etanercept
Eligibility
Inclusion Criteria:
- Have a diagnosis of chronic plaque-type psoriasis for at least 6 months (with or
without psoriatic arthritis [PsA]), prior to first administration of study
intervention, defined as having at screening and baseline, Investigator Global
Assessment (IGA) greater than or equal to (>=) 3, Psoriasis Area and Severity Index
(PASI) >=12, >=10% body surface area (BSA) involvement and at least one of the
following: very thick lesions, clinically relevant facial, genital, or hand/ foot
involvement, PASI>=20, >20% BSA involvement, or IGA=4
- Be a candidate for phototherapy or systemic treatment of plaque psoriasis (either
naive or history of previous treatment)
- Have plaque psoriasis considered by the investigator as inadequately controlled with
phototherapy and/or topical therapy after an adequate dose and duration of therapy
- Be considered, in the opinion of the investigator, a suitable candidate for etanercept
therapy, according to their country's approved Enbrel product labeling
- Be otherwise healthy on the basis of physical examination, medical history, and vital
signs performed at screening. Any abnormalities, must be consistent with the
underlying illness in the study population and this determination must be recorded in
the participant's source documents and initialed by the investigator
- Must have acceptable evidence of immunity to varicella and measles, mumps, and rubella
(MMR), which includes any one of the following: documentation of age-appropriate
vaccination that includes both doses of each vaccine (unless local guidelines specify
otherwise) or documentation of past infection by a healthcare provider or in the
absence of previous 2 criteria, participants must have positive protective antibody
titers to these infection prior to the first administration of study intervention. For
participants who have not completed the recommended vaccination schedule for varicella
and MMR, and the subsequent vaccination falls within the next 4 years, an accelerated
vaccination schedule must be completed prior to study enrollment if available and
required or strongly recommended for the location. If varicella or MMR vaccines are
utilized, it is necessary for 2 weeks to elapse between the vaccination and receipt of
study intervention
Exclusion Criteria:
- Currently has nonplaque forms of psoriasis (example, erythrodermic, guttate, or
pustular)
- Has current drug-induced psoriasis (example, a new onset of psoriasis or an
exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Has previously received guselkumab or etanercept
- Has a history of chronic or recurrent infectious disease, including but not limited to
chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent
urinary tract infection (recurrent pyelonephritis or chronic non-remitting cystitis),
fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin
wounds or ulcers
- Has a known history of lymphoproliferative disease, including lymphoma; a history of
monoclonal gammopathy of undetermined significance (MGUS); or signs and symptoms
suggestive of possible lymphoproliferative disease, such as lymphadenopathy or
splenomegaly
Ages Eligible for Study
6 Years - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pediatric Dermatology
650-723-0636
I'm interested
Pediatric Dermatology Clinical Trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Guselkumab
- drug: Placebo for guselkumab
- drug: Etanercept
Eligibility
Inclusion Criteria:
- Have a diagnosis of chronic plaque-type psoriasis for at least 6 months (with or
without psoriatic arthritis [PsA]), prior to first administration of study
intervention, defined as having at screening and baseline, Investigator Global
Assessment (IGA) greater than or equal to (>=) 3, Psoriasis Area and Severity Index
(PASI) >=12, >=10% body surface area (BSA) involvement and at least one of the
following: very thick lesions, clinically relevant facial, genital, or hand/ foot
involvement, PASI>=20, >20% BSA involvement, or IGA=4
- Be a candidate for phototherapy or systemic treatment of plaque psoriasis (either
naive or history of previous treatment)
- Have plaque psoriasis considered by the investigator as inadequately controlled with
phototherapy and/or topical therapy after an adequate dose and duration of therapy
- Be considered, in the opinion of the investigator, a suitable candidate for etanercept
therapy, according to their country's approved Enbrel product labeling
- Be otherwise healthy on the basis of physical examination, medical history, and vital
signs performed at screening. Any abnormalities, must be consistent with the
underlying illness in the study population and this determination must be recorded in
the participant's source documents and initialed by the investigator
- Must have acceptable evidence of immunity to varicella and measles, mumps, and rubella
(MMR), which includes any one of the following: documentation of age-appropriate
vaccination that includes both doses of each vaccine (unless local guidelines specify
otherwise) or documentation of past infection by a healthcare provider or in the
absence of previous 2 criteria, participants must have positive protective antibody
titers to these infection prior to the first administration of study intervention. For
participants who have not completed the recommended vaccination schedule for varicella
and MMR, and the subsequent vaccination falls within the next 4 years, an accelerated
vaccination schedule must be completed prior to study enrollment if available and
required or strongly recommended for the location. If varicella or MMR vaccines are
utilized, it is necessary for 2 weeks to elapse between the vaccination and receipt of
study intervention
Exclusion Criteria:
- Currently has nonplaque forms of psoriasis (example, erythrodermic, guttate, or
pustular)
- Has current drug-induced psoriasis (example, a new onset of psoriasis or an
exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Has previously received guselkumab or etanercept
- Has a history of chronic or recurrent infectious disease, including but not limited to
chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent
urinary tract infection (recurrent pyelonephritis or chronic non-remitting cystitis),
fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin
wounds or ulcers
- Has a known history of lymphoproliferative disease, including lymphoma; a history of
monoclonal gammopathy of undetermined significance (MGUS); or signs and symptoms
suggestive of possible lymphoproliferative disease, such as lymphadenopathy or
splenomegaly
Ages Eligible for Study
6 Years - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pediatric Dermatology
650-723-0636
I'm interested
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Guselkumab
- drug: Placebo for guselkumab
- drug: Etanercept
Eligibility
Inclusion Criteria:
- Have a diagnosis of chronic plaque-type psoriasis for at least 6 months (with or
without psoriatic arthritis [PsA]), prior to first administration of study
intervention, defined as having at screening and baseline, Investigator Global
Assessment (IGA) greater than or equal to (>=) 3, Psoriasis Area and Severity Index
(PASI) >=12, >=10% body surface area (BSA) involvement and at least one of the
following: very thick lesions, clinically relevant facial, genital, or hand/ foot
involvement, PASI>=20, >20% BSA involvement, or IGA=4
- Be a candidate for phototherapy or systemic treatment of plaque psoriasis (either
naive or history of previous treatment)
- Have plaque psoriasis considered by the investigator as inadequately controlled with
phototherapy and/or topical therapy after an adequate dose and duration of therapy
- Be considered, in the opinion of the investigator, a suitable candidate for etanercept
therapy, according to their country's approved Enbrel product labeling
- Be otherwise healthy on the basis of physical examination, medical history, and vital
signs performed at screening. Any abnormalities, must be consistent with the
underlying illness in the study population and this determination must be recorded in
the participant's source documents and initialed by the investigator
- Must have acceptable evidence of immunity to varicella and measles, mumps, and rubella
(MMR), which includes any one of the following: documentation of age-appropriate
vaccination that includes both doses of each vaccine (unless local guidelines specify
otherwise) or documentation of past infection by a healthcare provider or in the
absence of previous 2 criteria, participants must have positive protective antibody
titers to these infection prior to the first administration of study intervention. For
participants who have not completed the recommended vaccination schedule for varicella
and MMR, and the subsequent vaccination falls within the next 4 years, an accelerated
vaccination schedule must be completed prior to study enrollment if available and
required or strongly recommended for the location. If varicella or MMR vaccines are
utilized, it is necessary for 2 weeks to elapse between the vaccination and receipt of
study intervention
Exclusion Criteria:
- Currently has nonplaque forms of psoriasis (example, erythrodermic, guttate, or
pustular)
- Has current drug-induced psoriasis (example, a new onset of psoriasis or an
exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Has previously received guselkumab or etanercept
- Has a history of chronic or recurrent infectious disease, including but not limited to
chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent
urinary tract infection (recurrent pyelonephritis or chronic non-remitting cystitis),
fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin
wounds or ulcers
- Has a known history of lymphoproliferative disease, including lymphoma; a history of
monoclonal gammopathy of undetermined significance (MGUS); or signs and symptoms
suggestive of possible lymphoproliferative disease, such as lymphadenopathy or
splenomegaly
Ages Eligible for Study
6 Years - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pediatric Dermatology
650-723-0636
I'm interested
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Guselkumab
- drug: Placebo for guselkumab
- drug: Etanercept
Eligibility
Inclusion Criteria:
- Have a diagnosis of chronic plaque-type psoriasis for at least 6 months (with or
without psoriatic arthritis [PsA]), prior to first administration of study
intervention, defined as having at screening and baseline, Investigator Global
Assessment (IGA) greater than or equal to (>=) 3, Psoriasis Area and Severity Index
(PASI) >=12, >=10% body surface area (BSA) involvement and at least one of the
following: very thick lesions, clinically relevant facial, genital, or hand/ foot
involvement, PASI>=20, >20% BSA involvement, or IGA=4
- Be a candidate for phototherapy or systemic treatment of plaque psoriasis (either
naive or history of previous treatment)
- Have plaque psoriasis considered by the investigator as inadequately controlled with
phototherapy and/or topical therapy after an adequate dose and duration of therapy
- Be considered, in the opinion of the investigator, a suitable candidate for etanercept
therapy, according to their country's approved Enbrel product labeling
- Be otherwise healthy on the basis of physical examination, medical history, and vital
signs performed at screening. Any abnormalities, must be consistent with the
underlying illness in the study population and this determination must be recorded in
the participant's source documents and initialed by the investigator
- Must have acceptable evidence of immunity to varicella and measles, mumps, and rubella
(MMR), which includes any one of the following: documentation of age-appropriate
vaccination that includes both doses of each vaccine (unless local guidelines specify
otherwise) or documentation of past infection by a healthcare provider or in the
absence of previous 2 criteria, participants must have positive protective antibody
titers to these infection prior to the first administration of study intervention. For
participants who have not completed the recommended vaccination schedule for varicella
and MMR, and the subsequent vaccination falls within the next 4 years, an accelerated
vaccination schedule must be completed prior to study enrollment if available and
required or strongly recommended for the location. If varicella or MMR vaccines are
utilized, it is necessary for 2 weeks to elapse between the vaccination and receipt of
study intervention
Exclusion Criteria:
- Currently has nonplaque forms of psoriasis (example, erythrodermic, guttate, or
pustular)
- Has current drug-induced psoriasis (example, a new onset of psoriasis or an
exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Has previously received guselkumab or etanercept
- Has a history of chronic or recurrent infectious disease, including but not limited to
chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent
urinary tract infection (recurrent pyelonephritis or chronic non-remitting cystitis),
fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin
wounds or ulcers
- Has a known history of lymphoproliferative disease, including lymphoma; a history of
monoclonal gammopathy of undetermined significance (MGUS); or signs and symptoms
suggestive of possible lymphoproliferative disease, such as lymphadenopathy or
splenomegaly
Ages Eligible for Study
6 Years - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pediatric Dermatology
650-723-0636
I'm interested